How would you treat a young patient with metastatic colorectal cancer who initially tolerated 12 cycles of FOLFOX + bev with disease progression after cycle 3 of maintenance 5-FU + bev?

TRIBE and TRIBE2 studies showed convincing evidence of triplet chemotherapy FOLFOXIRI/bevacizumab has PFS, and more importantly, OS benefits for patients with metastatic colorectal cancer (mCRC) and now, this regimen has been used in our routine clinical practice more and more frequently especially ...